TNF-α inhibitors with anti-oxidative stress activity from natural products

Current Topics in Medicinal Chemistry

Volumn 12, Issue 13, 2012, Pages 1408-1421

  Li, Jing ^a   Zhang, Huibin ^b   Huang, Wenlong ^b   Qian, Hai ^b   Li, Ying ^c  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti oxidative stress; Natural products; TNF a inhibitors

Indexed keywords

BAICALEIN; CAFFEIC ACID PHENETHYL ESTER; CURCUMIN; CYANIDIN 3 GLUCOSIDE; EPIGALLOCATECHIN GALLATE; ERIODICTYOL; FLAVONOID; GAMMA INTERFERON; GENISTEIN; GLABRIDIN; HESPERETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LUTEOLIN; LUTEOLIN 7 GLUCOSIDE; NARINGENIN; NATURAL PRODUCT; POLYPHENOL; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROSMARINIC ACID; SCOPOLETIN; TERPENE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ANTIDIABETIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIULCER ACTIVITY; CHINESE MEDICINE; CYTOKINE PRODUCTION; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LIVER PROTECTION; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; BIOLOGICAL AGENTS; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864549415     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612801784434     Document Type: Review

References (108)

1. Hickenbottom, S. L.; Grotta, J. Neuroprotective therapy. Semin. Neurol. 1998, 18, 485-492.
2. Lidgren, L. Chronic inflammation, joint replacement and malignant lymphoma. J. Bone Joint Surg. Br. 2008, 90, 7-10.
3. Kaplan, A. P.; Kusuman, J.; Michael, S. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 2002, 109, 195-209.
4. Sattar, N.; McCarey David, W.; Capell, H.; Mclnnes Lain, B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 41, 2957-2963.
5. Frieri, M. Neuroimmunology and inflammation: implications for therapy of allergic and autoimmune diseases. Ann. Allergy, Asthma, Im. 2003, 90, 34-40.
6. Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldawer, L. L. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2003, 2, 736-746.
7. Atish, T. P.; Vikrantsinh, M. G.; Kamlesh, K. B. Modulating TNF-α signaling with natural products. Drug Discov. Today 2006, 12, 725-732.
8. Jones, E. Y.; Stuart, D. I.; Walker, N. P. C. Structure of tumor necrosis factor. Nature 1989, 338, 225-228.
9. Varfolomeev, E. E.; Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004, 116, 491-497.
10. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; Mcnulty, D.; Blumenthal, M. J.; Heyes, J. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
11. Herlaar, E.; Brown, Z. p38 MAPK signaling cascades in inflammatory disease. Mol. Med. Today 1999, 5, 439-447.
12. Lee, J. C.; Kumar, S; Griswold, D. E.; Underwood, D. C.; Votta, B. J.; Adams, J. L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000, 47, 185-201.
13. Rook, G. A. W.; Taverne, J.; Playfair, J. H. L. Evaluation of TNF as antiviral, antibacterial and antiparasitic agent. Biotherapy 1991, 3, 167-175.
14. Nokta, M.; Matzke, D.; Jennings, M.; Schlick, E.; Nadler, P. I.; Pollard, R. In vivo administration of tumor necrosis factor-α is associated with antiviral activity in human peripheral mononuclear cells. P. Soc. Exp. Biol. Med. 1991, 197, 144-149.
15. Liu, X. Y.; Shao, J. J.; Xiong, W.; Yu, S, Y.; Hu, Y. W.; Liu, J. X.; Wang, X.; Xiang, L.; Yuan, Z. H. Cellular clAP2 gene expression associated with anti-HBV activity of TNF-α in hepatoblastoma cells. J. Interf. Cytok. Res. 2005, 25, 617-626.
16. Deaubener, W.; Remscheid, C.; Nockeman, S.; Pilz, K.; Seghrouchni, S.; Mackenzie, C.; Hadding, U. Anti-parastitic effector mechanisms in human brain tumor cells: role of interferon-α and tumor necrosis factor. Eur. J. Immun. 1996, 26, 487-492.
17. Benedetto, N.; Folgore, A.; Carratelli, C. R.; Galdiero, F. Effects of cytokines and prolactin on the replication of Toxoplasma gondii in murine microglia. Eur. Cytokine Netw. 2001, 12, 348-358.
18. Nawroth, P. P.; Bank, I.; Handley, D.; Cassimeris, J.; Chess, L.; Stern, D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 1986, 163, 1362-1375.
19. Feldmann, M. The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target. J. R. Coll. Physicians Lond. 1996, 30, 560-570.
20. Butler, D. M.; Maini, R. N.; Feldmann, M.; Brennan, F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 1995, 6, 225-230.
21. Pober, J. S.; Lapierre, L. A.; Stolpen, A. H.; Brock, T. A.; Springer, T. A.; Fires, W.; Bevilacqua, M. P.; Mendrick, D. L.; Gimbrone, TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products Current Topics in Medicinal Chemistry, 2012, Vol. 12, No. 13 1419x
22. Gimbrone M. A. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J. Immunol. 1987, 138, 3319-3324.
23. Slowik, M. R.; De Luca, L. G.; Fiers, W.; Pober, J. S. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am. J. Pathol. 1993, 143, 1724-1730.
24. Nawroth, P.; Handley, D.; Matsueda, G.; De Waal, R.; Gerlach, H.; Blohm, D.; Stern, D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 1988, 168, 637-647.
25. Nawroth, P. P.; Stern, D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 1986, 163, 740-745.
26. Estrada, C.; Gomez, C.; Martin, C.; Moncada, S.; Gonzalez, C. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem. Biophys. Res. Commun. 1992, 186, 475-482.
27. Yoshizumi, M.; Perrella, M. A.; Burnett, J. C.; Lee, M. E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 1993, 73, 205-209.
28. Brett, J.; Gerlach, H.; Nawroth, P.; Steinberg, S.; Godman, G.; Stern, D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J. Exp. Med. 1989, 169, 1977-1991.
29. Goldblum, S. E.; Sun, W. L. Tumor necrosis factor-alpha augments pulmonary arterial transendothelial albumin flux in vitro. Am. J. Physiol. 1990, 258, L57-67.
30. Tracey, K. J.; Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 1994, 45, 491-503.
31. Bedard, P. A.; Golds, E. E. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblast. J. Cell. Physiol. 1993, 154, 433-441.
32. Hotamisligil, G. S.; Murray, D. L.; Choy, L. N.; Spiegelman, B. M. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 4854-4858.
33. Marletta, M. A. Nitric oxide synthase structure and mechanism. J. Biol. Chem. 1993, 268, 12231-12234.
34. Rahman, I. Beneficial effects of dietary polyphenols using lung inflammation as a model. J. Sci. Food Agric. 2006, 86, 2499-2502.
35. Moreira, P. I.; Honda, K.; Liu, Q.; Aliev, G.; Oliveira, C. R.; Santos, M. S.; Zhu, X. W.; Smith, M. A.; Perry, G. Alzheimer's disease and oxidative stress: the old problem remains unsolved. Curr. Med. Chem.-Central Nervous System Agents 2005, 5, 51-62.
36. Markesbery, W. R.; Carney, J. M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 1999, 9, 133-146.
37. Collamer, A. N.; Battafarano, D. F. The treatment of ankylosing spondylitis and psoriatic arthritis with etanercept: a comprehensive review. Clin. Med. Ther. 2009, 1, 27-43.
38. Licastro, F.; Chiappelli, M.; Ianni, M.; Porcellini, E. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules. Int. J. Immunopath. Ph. 2009, 22, 567-572.
39. Murdaca, G.; Colombo, B. M.; Puppo, F. Anti-TNF-α inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int. J. Immunopa. Ph. 2009, 22, 557-565.
40. Foley, P. A.; Quirk, C.; Sullivan, J. R.; Dolianitis, C.; Hack, S. P.; Thirunavukkarasu, K.; Cooper, A. J. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J. Eur. Acad. Dermatol. 2010, 24, 1135-1143.
41. Mrowietz, U.; Reich, K. Ten years of infliximab: Its role in dermatology. Eur. J. Pharmacol. 2009, 623, S10-S16.
42. Molloy, J. W.; Stengel, J. Z.; Arnold, H. L. Infliximab: a review of its use in the treatment of Crohn's disease. Clin. Med. Ther. 2009, 1, 1351-1365.
43. Poddubnyy, D. A.; Rudwaleit, M. Adalimumab for the treatment of psoriatic arthritis. Expert Rev. Clin. Immun. 2009, 5, 671-681.
44. Miyasaka, N. Adalimumab for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immun. 2009, 5, 19-26.
45. Kupper, H.; Salfeld, J.; Tracey, D.; Kalden, J. R. Adalimumab(Humira). Handbook of Therapeutic antibodies 2010, 697-732.
46. Davis, J. C. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin. Arthritis Rheu. 2004, 34, 668-677.
47. Anderson, P. J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin. Arthritis Rheu. 2005, 34, S19-22.
48. Zhang, W.; Tang, F. L. Progress of biological agents in treatment of rheumatoid immune diseases. Basic Clin. Med. 2006, 26, 931-937.
49. Shapiro, H.; Lev, S.; Cohen, J.; Singer, P. Polyphenols in the prevention and treatment of sepsis syndromes: Rationale and preclinical evidence. Nutrition 2009, 25, 981-997.
50. Nam, N. H. Naturally occurring NF-αB inhibitors. Mini-Reviews in Med. Chem. 2006, 6, 945-951.
51. Fujiki, H.; Suganuma, M.; Kurusu, M.; Okabe, S.; Imayoshi, Y.; Taniguchi, S.; Yoshida, T. New TNF-α releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutation Res. 2003, 523-524, 119-125.
52. Ran, Z. H.; Chen, C.; Xiao, S. D. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed. Pharmacother. 2008, 62, 189-196.
53. Cho, J. Y.; Kim, P. S.; Park, J.; Yoo, E. S.; Baik, K. U.; Kim, Y. K.; Park, M. H. Inhibitor of tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW 264.7 cells from Amorpha fruticosa. J. Ethnopharmacol. 2000, 70, 127-133.
54. Yalniz, M.; Bahcecioglu, I. H.; Kuzu, N.; Poyrazoglu, O. K.; Bulmus, O.; Celebi. S.; Ustundag, B.; Ozercan, I. H.; Sahin, K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J. Gastroen. Hepatol. 2007, 22, 2009-2014.
55. Ruetten, H.; Thiemermann, C. Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rats: a possible role for protein tyrosine kinase. Br. J. Pharmacol. 1997, 122, 59-70.
56. Chen, L. Y.; Zuraw, B. L.; Zhao, M.; Liu, F. T.; Huang, S.; Pan, Z. K. Involvement of protein tyrosine kinase in Toll-like receptor 4-mediated NF-kappa B activation in human peripheral blood monocytes. Am. J. Physiol. Lung Cell Mol. Physiol. 2003, 284, L607-613.
57. Bagchi, D.; Sen, C. K.; Bagchi, M.; Atalay, M. Anti-angiogenic, antioxidant, and anti-carcinogenic properties of a novel anthocyanin-rich berry extract formula. Biochemistry (Moscow) 2004, 69, 75-80.
58. Hou, D. X. Potential mechanisms of cancer chemoprevention by anthocyanins. Curr. Mol. Med. 2003, 2, 149-159.
59. Ding, M.; Feng, R. T.; Wang, S. Y.; Bowman, L.; Lu, Y. J.; Qian, Y.; Castranova, V.; Jiang, B. H.; Shi, X. L. Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity. J. Biological Chem. 2006, 281, 17359-17368.
60. Guo, H. H.; Ling, W. H.; Wang, Q.; Liu, C.; Hu, Y.; Xia, M. Cyanidin 3-glucoside protects 3T3-L1 adipocytes against H2O2-or TNF-α-induced insulin resistance by inhibiting c-Jun NH2-terminal kinase activation. Biochem. Pharmacol. 2008, 75, 1393-1401.
61. Yokota, T.; Nishio, H.; Kubota, Y.; Mizoguchi, M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigm. Cell Res. 1998, 11, 355-361.
62. Fukai, T.; Marumo, A.; Kaitou, K.; Kanda, T.; Terada, S.; Nomura, T. Antimicrobial activity of licorice flavonoids against methicillinresistant Staphylococcus aureus. Fitoterapia 2002, 73, 536-539.
63. Rosenblat, M.; Belinky, P.; Vaya, J.; Levy, R.; Hayek, T.; Coleman, R.; Merchav, S.; Aviram, M. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cellmediated oxidation of low density lipoprotein: A possible role for protein kinase C. J. Biol. Chem. 1999, 274, 13790-13799.
64. Fukai, T.; Satoh, K.; Nomura, T.; Sakagami, H. Preliminary evaluation of antinephritis and radical scavenging activities of glabridin from Glycyrrhiza glabra. Fitoterapia 2003, 74, 624-629.
65. Kang, J. S.; Yoon, Y. D.; Cho, I. J.; Han, M. H.; Lee, C. W.; Park, S. K.; Kim, H. M. Glabridin, an isoflavan from licorice root, inhibits inducible nitric-oxide synthase expression and improves sur vival of mice in experimental model of septic shock. J. Pharmacol. Exp. Ther. 2005, 312, 1187-1194.
66. Park S. H.; Kang J. S.; Yoon Y. D.; Lee K.; Kim K. J.; Lee K. H.; Lee C. W.; Moon E.Y.; Han S. B.; Kim B. H.; Kim H. M.; Park S. K. Glabridin inhibits lipopolysaccharide-induced activation of a microglial cell line, BV-2, by blocking NF-kappB and AP-1. Phytother. Res. PTR 2010, 24, S29-34.
67. Yu, X. Q.; Xue, C. C.; Zhou, Z. W.; Li, C. G.; Du, Y. M.; Liang, J.; Zhou, S. F. In vitro and in vivo neuroprotective effect and mechanisms of glabridin, a major active isoflavan from Glycyrrhiza glabra (licorice). Life Sci. 2008, 82, 68-78.
68. Mu, M. M.; Chakravortty, D. S.; Sugiyama, T.; Koide, N.; Takahashi, K.; Mori, I.; Yoshida, T.; Yokochi, T. The inhibitory action of quercetin on lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cell. J. Endotoxin Res. 2001, 7, 431-438.
69. Barclay, L. R.; Vinqvist, M. R.; Mukai, K.; Goto, H.; Hashimoto, Y.; Tokunaga, A.; Uno, H. On the antioxidant mechanism of curcumin: classical methods are needed to determine antioxidant mechanism and activity. Org. lett. 2000, 2, 2841-2843.
70. Dunsmore, K. E.; Chen, P. G.; Wong, H. R. Curcumin, a medicinal herbal compound capable of inducing the heat shock response. Crit. Care Med. 2001, 29, 2199-2204.
71. Siddiqui, A. M.; Cui, X.; Wu, R.; Dong, W.; Zhou, M.; Hu, M.; Simms, H. H.; Wang, P. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferators-activated receptor-gamma. Crit. Care Med. 2006, 34, 1874-1882.
72. Weber, W. M.; Hunsaker, L. A.; Roybal, C. N.; Bobrovnikova-Marjon, E. V.; Abcouwer, S. F.; Royer, R. E.; Deck, L. M.; Vander Jagt, D. L.; Activation of NFB is inhibited by curcumin and related enones. Bioorg. Med. Chem. 2006, 14, 2450-2461.
73. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B. B. Suppression of 7, 12-dimethylbenz(a)-anthrancene-induced mammary carcinogenesis in rats by resveratrol: a role of nucleaer factor-B, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002, 62, 4945-4954.
74. Jang, M.; Pezzuto, J. M. Effects of resveratrol on 12-Otetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett. 1998, 134, 81-89.
75. Holmes-Mcnary, M.; Baldwin, A. S. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IB kinase. Cancer Res. 2000, 60, 3477-3483.
76. Maffia, P.; Lanaro, A.; Pisano, B.; Borrelli, F.; Capasso, F.; Pinto, A.; Ialenti, A. Beneficial effects of caffeic acid phenethyl ester in a rat model of vascular injury. Br. J. Pharmacol. 2002, 136, 353-360.
77. Osakabe, N.; Yasuda, A.; Natsume, M.; Sanbongi, C.; Kato, Y.; Osawa, T.; Yoshikawa, T. Rosmarinic acid, a major polyphenolic component of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)-sensitized mice. Free Radical Bio. Med. 2002, 33, 789-806.
78. Zdarilová, A.; Svobodová, A.; Šimánek, V.; Ulrichová, J. Prunella vulgaris extract and rosmarinic acid suppress lipopolysaccharideinduced alteration in human gingival fibroblasts. Toxicol. in Vitro 2009, 23, 386-392.
79. Schmidt, T. J. Structure-activity relationships of sesquiterpene lactones. Stud. Nat. Prod. Chem. 2006, 33, 309-392.
80. Brinkel, A. M.; Ma, J.; Lipsky, P. E.; Raskin, I. Medicinal chemistry and pharmacology of genus Tripterygium (celastraceae). Phytochemistry 2007, 68, 732-766.
81. Li, X. Y. Anti-inflammatory and immunosuppressive components of Triperygium wilfordii hook F. Int. J. Immunother. 1993, 9, 181-187.
82. Jin, H. Z.; Hwang, B. Y.; Kim, H. S.; Lee, J. H.; Kim, Y. H.; Lee, J. J. Antiinflammatory constituents of celastrus orbiculatus inhibit the NF-kappaB activation and NO production. J. Nat. Prod. 2002, 65, 89-91.
83. Tsai, H. R.; Yang, L. M.; Tsai, W. J.; Chiou, W. F. Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. Eur. J. Pharmacol. 2004, 498, 45-52.
84. Chiou, W. F.; Chen, C. F.; Lin, J. J. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br. J. Pharmacol. 2000, 129, 1553-1560.
85. Qin, L. H.; Kong, L.; Shi, G. J.; Wang, Z. T.; Ge, B. X. Andrographolide inhibits the production of TNF-α and interleukin-12 in lipopolysaccharide-stimulated macrophages: role of mitogenactivated protein kinases. Biol. Pharm. Bull. 2006, 29, 220-224.
86. Hidalgo, M. A.; Romero, A.; Figueroa, J.; Cortés, P.; Concha, I. I.; Hancke, J. L.; Burgos, R. A. Andrographolide interferes with binding of nuclear factor-B to DNA in HL-60-derived neutrophilic cells. Br. J. Pharmacol. 2005, 144, 680-686.
87. Wu, J. N.; Liu, S. Z.; Li, L. Z.; Luo, D. S.; Shu, S. J. The protective effects of andrographolide on rat experimental myocardial ischemia models. Res. Traditional Chin. Med. 1996, 4, 61-64.
88. Zou, H.; Yuan, Z. B. Investigation on electrochemical behavior of andrographolide. Anal. Lab. 1997, 16, 1-4.
89. Xu, H.; Wang, X. Y.; Huang, W. L.; Zhang, H. B.; Guo, Q. L.; Liu, W. Synthesis and antitumor activity of N-acetyl-12-aminomethyl-14-deoxy andrographolide derivatives. J. China Pharm. Univ. 2005, 36, 496-499.
90. Xu, H.; Huang, W. L.; Zhang, H. B.; Zhou, J. P. Synthesis of the derivatives of andrographolide for NO donor. Chin. J. Org. Chem. 2005, 25, 1386-1391.
91. Wang, X. Y.; Xu, H.; Wu. X. M.; Huang, W. L.; Zhou, J. P. Synthesis and antitumor activity of isoandrographolide compounds. J. China Pharm. Univ. 2005, 36, 504-510.
92. Li, J.; Huang, W. L.; Zhang, H. B.; Wang, X. Y.; Zhou, H. P. Synthesis of andrographolide derivatives and their TNF-α and IL-6 expression inhibitory activities. Bioorg. Med. Chem. Lett. 2007, 17, 6891-6894.
93. Li, J.; Huang, W. L.; Zhang, H. B.; Zhou, H. P. Synthesis of amide derivatives of andrographolide and their inhibitory activities on COX-2 expression. J. China Pharm. Univ. 2007, 38, 299-304.
94. Gao, D. W.; Li, Q. W,; Li, Y.; Liu, Z. H; Liu, Z. W; Fan, Y. S.; Han, Z. S.; Li, J.; Li, K. Antidiabetic potential of oleanolic acid from Ligustrum lucidum Ait. Can. J. Physiol. Pharmacol. 2007, 85, 1076-1083.
95. Liu, J.; Sun, H. B.; Wang, X. F.; Mu, D. Y.; Liao, H.; Zhang, L. Y. Effects of oleanolic acid and meslinic acid on hyperlipidemia. Drug. Dev. Res. 2007, 68, 261-266.
96. Sun, H. B. Drug discovery based on pharmacological interference with glycometabolism. J. China Pharm. Univ. 2006, 37, 1-8.
97. Choi, C. Y.; You, H. J.; Jeong, H. G. Nitric oxide and tumor necrosis factor-α production by oleanolic acid via nuclear factor-B activation in macrophages. Biochem. Biophys. Res. Commun. 2001, 288, 49-55.
98. Li, Y.; Ohizumi, Y. Search for constituents with neurotrophic factor-potentiating activity from the medicinal plants of Paraguay and Thailand. Yakugaku Zasshi 2004, 124, 417-424.
99. Kang, B. Y.; Chung, S. W.; Kim, S. H.; Ryu, S. Y.; Kim, T. S. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from salvia miltiorrhiza. Immunopharmacology 2000, 49, 355-361.
100. Bai, A. P.; Lu, N. H.; Guo, Y.; Fan, X. M. Tanshinone IIA ameliorates trinitrobenzene sulfonic acid (TNBS)-induced murine colitis. Dig. Dis. Sci. 2008, 53, 421-428.
101. Du, Z. Y.; Li, X. Y. Effects of ginkgolides on interleukine-1, tumor necrosis factor-α and nitric oxide production by rat microglia stimulated with lipopolysaccharides in vitro. Arzneim-Forsch/Drug Res. 1998, 48, 1126-1130.
102. Zhao, H. W.; Li, X. Y. Ginkgolide A, B and huperzine A inhibit nitric oxide production from rat C6 and human BT325 glioma cells. Acta. Pharmacol. Sin. 1999, 20, 941-943.
103. Zhou, L. J.; Song, W.; Zhu, X. Z. Protective effects of bilobalide on amyloid beta peptide-induced PC12 cell cytotoxicity. Acta. Pharmacol. Sin. 2000, 21, 75-79.
104. Yeh, Y. C.; Liu, T. J.; Wang, L. C.; Lee, H. W.; Ting, C. T.; Lee, W. L.; Hung, C. J.; Wang, K. Y.; Lai, H. C.; Lai, H. C. A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes. Br. J. Pharmacol. 2009, 156, 48-61.
105. Yin, H. Q.; Je, Y. T.; Kim, Y. C.; Shin, Y. K.; Sung, S. H.; Lee, K. Y.; Jeone, G. S.; Kim, Y. C.; Lee, B. H. Magnolia officinalis reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element-binding protein-1c. J. Pharmacol. Sci. 2009, 109, 486-495.
106. Xu, M. Z.; Lee, W. S.; Han, J. M.; Oh, H. W.; Park, D. S.; Tian, G. R.; Jeong, T. S.; Park, H. Y. Antioxidant and anti-inflammatory activities of N-acetyldopamine dimmers from periostracum cicadae. Bioorg. Med. Lett. 2006, 14, 7826-7834.
107. Sampath, P. D.; Vijayaragavan, K. Ameliorative prospective of alpha-mangostin, a xanthone derivative from Garcinia mangostana against α-adrenergic catecholamine-induced myocardial toxicity and anomalous cardiac TNF-α and COX-2 expressions in rats. Exp. Toxicol. Pathol. 2008, 60, 357-364.
108. Kim, S.; Choi, M. G.; Lee, H. S.; Lee, S.; Kim, S. H.; Kim, W. W.; Hur, S. M.; Kim, J. H.; Choe, J. H.; Nam, S. J.; Yang, J. H.; Kim, S.; Lee, J. E.; Kim, J. S. Silibinin suppresses TNF-α-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway. Molecules 2009, 14, 4300-4311.